Table 2.

Actionable alterations in 36 patients with melanoma.

PathwayGeneAlteration# Cases
MEKBRAFV600E2
(n = 16, 44%)NRASQ61R1
NRASG12D1
NRASG12S1
NRASG13D1
NRASG13R1
NRASQ61K2
NRASQ61L1
HRASQ61L2
KITD816V1
KITK642E3
KITK693N1
MAP2K1R49H1
NF1Q1499X1
NF1Q2213X1
NF1Q236X1
NF1Y489C1
KRASAmplification2
METAmplification1
Cell cycleCDKN2AR80X1
(n = 11, 30%)CDK4Amplification2
CDKN2ADeletion8
RTKsFGFR2E619K1
(n = 8, 22%)KDRAmplification2
PDGFRAAmplification3
PI3K/mTORPIK3CAH1047R1
(n = 3, 8%)PTENM1R1
PTENR173C1
PTENSplicing1
p53 (n = 2, 6%)MDM2Amplification2
DNA repair (n = 1, 3%)MSH6T955fs1